| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Elena Antelmi, Giuseppe Plazzi, Fabio Pizza, Stefano Vandi, Debora Aricò, Raffaele Ferr. Impact of acute administration of sodium oxybate on heart rate variability in children with type 1 narcolepsy. Sleep medicine. vol 47. 2019-10-21. PMID:29880141. |
currently, cardiovascular measurements in children affected with type 1 narcolepsy (nt1) have never been investigated, and neither have their modulation by the administration of sodium oxybate (so). |
2019-10-21 |
2023-08-13 |
Not clear |
| Ilaria Bartolini, Fabio Pizza, Andrea Di Luzio, Giulia Neccia, Elena Antelmi, Stefano Vandi, Giuseppe Plazz. Automatic detection of cataplexy. Sleep medicine. vol 52. 2019-10-21. PMID:30195199. |
although being the most specific symptom of narcolepsy type 1 (nt1), cataplexy is currently investigated by clinical interview only, with potential diagnostic pitfalls. |
2019-10-21 |
2023-08-13 |
human |
| Damien Leger, Caroline Gauriau, Lorenzo Tonetti, Michaele Lantin, Marco Filardi, Pierre Philip, Brice Faraut, Vincenzo Natal. Using actigraphy to assess sleep and wake rhythms of narcolepsy type 1 patients: a comparison with primary insomniacs and healthy controls. Sleep medicine. vol 52. 2019-10-21. PMID:30286385. |
it has been shown that actigraphy may have a discriminant function (ds) for the diagnosis of narcolepsy type 1 patients (nt1), based on a combination of nighttime and daytime parameters. |
2019-10-21 |
2023-08-13 |
Not clear |
| Lucie Barateau, Isabelle Jaussent, Régis Lopez, Elisa Evangelista, Sofiene Chenini, Meriem Benkiran, Denis Mariano-Goulart, Yves Dauvillier. Cardiac Sympathetic Activity differentiates Idiopathic and Symptomatic Rapid Eye Movement Sleep Behaviour Disorder. Scientific reports. vol 8. issue 1. 2019-10-14. PMID:29740055. |
the pathophysiology of rapid eye movement sleep behavior disorder (rbd) associated with narcolepsy type 1 (nt1) is still poorly understood, potentially distinct from idiopathic rbd (irbd), but may share affected common pathways. |
2019-10-14 |
2023-08-13 |
human |
| Monica Moresco, Mariangela Lecciso, Darina Ocadlikova, Marco Filardi, Silvia Melzi, Birgitte Rahbek Kornum, Elena Antelmi, Fabio Pizza, Emmanuel Mignot, Antonio Curti, Giuseppe Plazz. Flow cytometry analysis of T-cell subsets in cerebrospinal fluid of narcolepsy type 1 patients with long-lasting disease. Sleep medicine. vol 44. 2019-09-26. PMID:29530370. |
type 1 narcolepsy (nt1) is a central hypersomnia linked to the destruction of hypocretin-producing neurons. |
2019-09-26 |
2023-08-13 |
Not clear |
| Fabian Büchele, Christian R Baumann, Rositsa Poryazova, Esther Werth, Philipp O Valk. Remitting narcolepsy? Longitudinal observations in a hypocretin-deficient cohort. Sleep. vol 41. issue 9. 2019-09-25. PMID:29868885. |
narcolepsy type 1 (nt1) is considered a chronic, incurable disease. |
2019-09-25 |
2023-08-13 |
Not clear |
| Hilde T Juvodden, Dag Alnæs, Martina J Lund, Ingrid Agartz, Ole A Andreassen, Espen Dietrichs, Per M Thorsby, Lars T Westlye, Stine Knudse. Widespread white matter changes in post-H1N1 patients with narcolepsy type 1 and first-degree relatives. Sleep. vol 41. issue 10. 2019-09-24. PMID:30016530. |
to assess white matter involvement in h1n1-vaccinated hypocretin deficient patients with narcolepsy type 1 (nt1) compared with first-degree relatives (a potential risk group) and healthy controls. |
2019-09-24 |
2023-08-13 |
Not clear |
| Sebjørg Hesla Nordstrand, Berit Hjelde Hansen, Yusman Kamaleri, Kristian Bernhard Nilsen, Terje Rootwelt, Tor-Ivar Karlsen, Stine Knudse. Changes in quality of life in individuals with narcolepsy type 1 after the H1N1-influenza epidemic and vaccination campaign in Norway: a two-year prospective cohort study. Sleep medicine. vol 50. 2019-09-13. PMID:30075393. |
we aimed to describe changes in hrqol after two years of multidisciplinary follow-up in a cohort of mainly post-h1n1 vaccination narcolepsy type-1 (nt1) patients in norway. |
2019-09-13 |
2023-08-13 |
Not clear |
| Adriana Bosco, Régis Lopez, Lucie Barateau, Sofiene Chenini, Carole Pesenti, Jean-Louis Pépin, Isabelle Jaussent, Yves Dauvillier. Effect of psychostimulants on blood pressure profile and endothelial function in narcolepsy. Neurology. vol 90. issue 6. 2019-07-23. PMID:29321233. |
to assess the effect of psychostimulant treatments on the 24-hour blood pressure (bp) profile of patients with narcolepsy type 1 (nt1). |
2019-07-23 |
2023-08-13 |
Not clear |
| Marco Filardi, Fabio Pizza, Elena Antelmi, Raffaele Ferri, Vincenzo Natale, Giuseppe Plazz. In-field assessment of sodium oxybate effect in pediatric type 1 narcolepsy: an actigraphic study. Sleep. vol 41. issue 6. 2019-05-15. PMID:29522206. |
sodium oxybate (sxb) is a gabaergic agent widely used as off-label treatment in pediatric type 1 narcolepsy (nt1). |
2019-05-15 |
2023-08-13 |
Not clear |
| Natasja Wulff Pedersen, Anja Holm, Nikolaj Pagh Kristensen, Anne-Mette Bjerregaard, Amalie Kai Bentzen, Andrea Marion Marquard, Tripti Tamhane, Kristoffer Sølvsten Burgdorf, Henrik Ullum, Poul Jennum, Stine Knudsen, Sine Reker Hadrup, Birgitte Rahbek Kornu. CD8 Nature communications. vol 10. issue 1. 2019-04-08. PMID:30783092. |
cd8 narcolepsy type 1 (nt1) is a neurological sleep disorder, characterized by the loss of hypocretin/orexin signaling in the brain. |
2019-04-08 |
2023-08-13 |
Not clear |
| Monica Moresco, Fabio Pizza, Elena Antelmi, Giuseppe Plazz. Sodium Oxybate Treatment in Pediatric Type 1 Narcolepsy. Current drug metabolism. vol 19. issue 13. 2019-02-28. PMID:29512449. |
narcolepsy type 1 (nt1) is a chronic neurologic disorder defined by excessive daytime sleepiness, cataplexy, sleep paralysis, hallucinations and disrupted nocturnal sleep, typically with onset during childhood/ adolescence. |
2019-02-28 |
2023-08-13 |
Not clear |
| P Medrano-Martinez, M J Ramos-Platon, R Peraita-Adrado. [Neuropsychological alterations in narcolepsy with cataplexy: a review]. Revista de neurologia. vol 66. issue 3. 2019-01-02. PMID:29368327. |
to describe the current state of the art about the main cognitive deficits that appear in patients affected with narcolepsy with cataplexy (nt1). |
2019-01-02 |
2023-08-13 |
Not clear |
| Régis Lopez, Anis Doukkali, Lucie Barateau, Elisa Evangelista, Sofiene Chenini, Isabelle Jaussent, Yves Dauvillier. Test-Retest Reliability of the Multiple Sleep Latency Test in Central Disorders of Hypersomnolence. Sleep. vol 40. issue 12. 2018-12-31. PMID:29099966. |
to assess the test-retest reliability of the polysomnography-multiple sleep latency test (psg-mslt) diagnostic classification and measures and to study the determinants of its variability in patients with narcolepsy type 1 (nt1) or with noncataplectic central disorders of hypersomnolence (nchs): type 2 (nt2), idiopathic hypersomnia (ih), and unspecified hypersomnolence (unspecified excessive daytime sleepiness [unseds]). |
2018-12-31 |
2023-08-13 |
Not clear |
| Thomas Rossor, Ming Lim, Kirandeep VanDenEshof, Paul Gringra. Pseudotumor cerebri syndrome in a patient with narcolepsy type 1. European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society. vol 22. issue 1. 2018-07-02. PMID:29195824. |
type 1 narcolepsy (nt1) is a chronic primary disorder of hypersomnolence characterized by excessive daytime sleepiness, cataplexy, sleep paralysis, hypnagogic hallucinations and disrupted nocturnal sleep. |
2018-07-02 |
2023-08-13 |
human |
| Lucie Barateau, Roland Liblau, Christelle Peyron, Yves Dauvillier. Narcolepsy Type 1 as an Autoimmune Disorder: Evidence, and Implications for Pharmacological Treatment. CNS drugs. vol 31. issue 10. 2018-06-07. PMID:28940143. |
narcolepsy type 1 (nt1) is a rare sleep disorder caused by the very specific loss of hypothalamic hypocretin (hcrt)/orexin neurons. |
2018-06-07 |
2023-08-13 |
human |
| Julie Anja Engelhard Christensen, Miki Nikolic, Mathias Hvidtfelt, Birgitte Rahbek Kornum, Poul Jennu. Sleep spindle density in narcolepsy. Sleep medicine. vol 34. 2018-03-07. PMID:28522097. |
patients with narcolepsy type 1 (nt1) show alterations in sleep stage transitions, rapid-eye-movement (rem) and non-rem sleep due to the loss of hypocretinergic signaling. |
2018-03-07 |
2023-08-13 |
Not clear |
| Julie Anja Engelhard Christensen, Miki Nikolic, Mathias Hvidtfelt, Birgitte Rahbek Kornum, Poul Jennu. Sleep spindle density in narcolepsy. Sleep medicine. vol 34. 2018-03-07. PMID:28522097. |
we aimed to evaluate whether the sleep spindle (ss) density is altered in patients with nt1 compared to controls and patients with narcolepsy type 2 (nt2). |
2018-03-07 |
2023-08-13 |
Not clear |
| Y Dauvilliers, C Gaig, L Barateau, F Graus, A Iranzo, R Lopez, J Santamari. Absence of NMDA receptor antibodies in the rare association between Type 1 Narcolepsy and Psychosis. Scientific reports. vol 6. 2018-01-26. PMID:27143278. |
frequency and mechanisms underlying the association between narcolepsy type 1 (nt1) and psychosis remain unclear with potential role for a common immune pathway. |
2018-01-26 |
2023-08-13 |
Not clear |
| Yves Dauvilliers, Elisa Evangelista, Regis Lopez, Lucie Barateau, Sabine Scholz, Barbara Crastes de Paulet, Bertrand Carlander, Isabelle Jaussen. Vitamin D deficiency in type 1 narcolepsy: a reappraisal. Sleep medicine. vol 29. 2018-01-05. PMID:28153207. |
narcolepsy type 1 (nt1) is considered to be an immune-mediated disease in which environmental factors, such as vitamin d, might play a major role. |
2018-01-05 |
2023-08-13 |
Not clear |